Rilapladib
- Generic Name
- Rilapladib
- Drug Type
- Small Molecule
- Chemical Formula
- C40H38F5N3O3S
- CAS Number
- 412950-08-4
- Unique Ingredient Identifier
- O14CWE893Z
- Background
Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
- Indication
Investigated for use/treatment in atherosclerosis and cardiovascular disorders.
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02130661
A Study to Assess the Effect of SB 659032 on Platelet Function
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT01750827
- Locations
- 🇺🇸
GSK Investigational Site, Lenexa, Kansas, United States
SB-659032 Platelet Aggregation Study
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT01745458
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 124
- Registration Number
- NCT01428453
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
- Conditions
- Atherosclerosis
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 83
- Registration Number
- NCT00695305
- Locations
- 🇺🇸
GSK Investigational Site, Warwick, Rhode Island, United States
Effect Of Rilapladib (SB-659032) On Platelet Aggregation
- Conditions
- AtherosclerosisHealthy Subjects
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT00387257
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.